Praluent, the Next Expensive "Game Changer," Blockbuster," "New Hope," - But Not Yet Shown to Benefit Patients

aliromucab evidence-based medicine health care prices manipulating clinical research PCSK9 inhibitor Praluent Regeneron Sanofi-Aventis

Praluent, the Next Expensive "Game Changer," Blockbuster," "New Hope," - But Not Yet Shown to Benefit Patients

Unknown 8/06/2015 Komentar

Here we go again.  The same month that it approved Entresto (look here), the US Food and Drug Administration approved a new PCSK9 inhibitor cholesterol lowering agent, alirocumab, immediately marketed as the pricy Praluent...

Baca selengkapnya

Entresto: Blockbuster, or Just Over Hyped? - Whatever, It Will Cost $4500 a Year

CHF clinical trials Entresto evidence-based medicine manipulating clinical research Novartis sacubitril

Entresto: Blockbuster, or Just Over Hyped? - Whatever, It Will Cost $4500 a Year

Unknown 7/30/2015 Komentar

The newest drug for congestive heart failure, Entresto, a fixed combination of valsartan and sacubitril, has just hit the market at an elevated price.  Like other drugs recently introduced as blockbusters, the high...

Baca selengkapnya

Bill Clinton, Paid to Speak to Biotech Conference, Extolled $1000 Pill to Prevent "Liver Rot," Despite Lack of Evidence that It Does

Clinton Foundation evidence-based medicine Gilead hepatitis C Sovaldi

Bill Clinton, Paid to Speak to Biotech Conference, Extolled $1000 Pill to Prevent "Liver Rot," Despite Lack of Evidence that It Does

Unknown 7/02/2015 Komentar

What were they thinking?Former President Clinton Talkes to Pharma and Biotech Executives In mid June, 2015, the Philadelphia Inquirer reported that former US PresidentClinton was the keynote speaker at Klick Ideas Exchange,...

Baca selengkapnya

academic corruption conflict of interest evidence-based medicine institutional conflicts of interest NEJM pharmaceuticals physicians

Unknown 5/19/2015 Komentar

Why is the New England Journal of Medicine Scolding "Pharmascolds"?I, a normally quiet blogger on this site, was disquieted by what may be a backlash aimed at quashing the anti-conflict-of-interest...

Baca selengkapnya

Promoting Amphetamines for Over-Eating - What Could Possibly Go Wrong?

clinical trials conflicts of interest deception evidence-based medicine FDA marketing Shire stealth marketing

Promoting Amphetamines for Over-Eating - What Could Possibly Go Wrong?

Unknown 2/27/2015 Komentar

Every day seems to bring the latest breathlessly touted innovation in modern health care.  The endless hawking of new health care wonders is beginning to inspire some skepticism, but maybe not enough.The Promotion of...

Baca selengkapnya

Logical Fallacies in Defense of Aggresive Screening for and Treatment of Hepatitis C

anechoic effect evidence-based medicine hepatitis C logical fallacies Sovaldi

Logical Fallacies in Defense of Aggresive Screening for and Treatment of Hepatitis C

Unknown 1/22/2015 Komentar

And the hepatitis C follies continue... As we have frequently written, most recently last week, the hepatitis C screening and treatment bandwagon keeps rolling along.  There is constant public argument about the prices...

Baca selengkapnya

The Fashion Challenges of the Emperor of Hepatitis C Treatment - Now in the BMJ, but Who Will Notice?

clinical trials evidence-based medicine health care prices hepatitis C Sovaldi

The Fashion Challenges of the Emperor of Hepatitis C Treatment - Now in the BMJ, but Who Will Notice?

Unknown 1/16/2015 Komentar

As we wrote, most recently last week, the hepatitis C screening and treatment bandwagon keeps rolling along.  There is constant public argument about the prices of treatment regimens, which approach $100,000 per patient...

Baca selengkapnya